Sponsors

Sponsorship packages for the 2026 conference are available:

Click here to see the 2026 options
Sponsors List
Compliance / Codex Publication List

Gold Sponsors 2026

About Acuitas Therapeutics

Acuitas Therapeutics Inc., the global leader in lipid nanoparticle (LNP) delivery systems for nucleic acid therapeutics, is a Vancouver-based company collaborating with pharmaceutical and biotech companies, academic researchers, and global health organizations to advance a broad range of medicines for a variety of diseases.

Acuitas’ clinically validated LNP technology has had a profound global impact — most notably enabling the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in more than 180 countries. Its technology also enables ONPATTRO® by Alnylam Pharmaceuticals, the first FDA-approved RNAi therapeutic for treating the rare and fatal disease transthyretin amyloidosis. More recently, Acuitas’ LNP technology has delivered other groundbreaking firsts: the first in-human proof of concept for genome base editing and the first personalized CRISPR therapy.

Today, Acuitas is advancing next-generation LNP to support a variety of therapeutic modalities. This includes targeted LNP for extrahepatic therapies such as in vivo CAR T-cells, gene editing therapies across multiple DNA editing technologies, epigenetic medicines to modulate gene expression without altering DNA, and multivalent vaccines for infectious diseases — such as malaria, HIV/AIDS, and tuberculosis — as well as oncology vaccines, including personalized cancer vaccines.

For more information, visit www.acuitastx.com.

Aldevron is a premier manufacturing partner, producing high-quality plasmid DNA, mRNA, proteins, and other key components for the development of vaccines, gene and cell therapies, immunotherapies and other treatments. As a part of the Danaher Corporation (NYSE: DHR) family of global science and technology companies, Aldevron supports thousands of scientists who are developing revolutionary, lifesaving treatments for millions of people. To learn more about how Aldevron is advancing biological science, visit www.aldevron.com/about-us.

FUJIFILM Corporation offers cutting-edge mRNA/LNP services. There is a variety of proprietary ionizable lipids available, like ones for vaccine use already in Phase 3, ones for i.v. with more expression in the liver and lower liver enzyme elevation in NHP, ones for liver de-targeting, and ex-vivo LNPs for KO/KI.
CDMO services from laboratory to commercial use are also available with high-quality and dedicated customer support.

Vazyme (688105.SH) is a global biotech supplier dedicated to advancing life science through innovative enzyme technology. To meet the varying needs of our customers and partners, we have developed over 1,000 types of genetically engineered recombinant enzymes, over 3,000 types of high-performance materials, and nearly 3,000 end products. By upholding rigorous quality standards and producing all molecular materials in-house, we guarantee a consistent and dependable supply to our global customers. 

FUJIFILM Corporation offers cutting-edge mRNA/LNP services. There is a variety of proprietary ionizable lipids available, like ones for vaccine use already in Phase 3, ones for i.v. with more expression in the liver and lower liver enzyme elevation in NHP, ones for liver de-targeting, and ex-vivo LNPs for KO/KI.
CDMO services from laboratory to commercial use are also available with high-quality and dedicated customer support.

Vazyme (688105.SH) is a global biotech supplier dedicated to advancing life science through innovative enzyme technology. To meet the varying needs of our customers and partners, we have developed over 1,000 types of genetically engineered recombinant enzymes, over 3,000 types of high-performance materials, and nearly 3,000 end products. By upholding rigorous quality standards and producing all molecular materials in-house, we guarantee a consistent and dependable supply to our global customers. 

Silver Sponsors 2026

ARCALIS is a CDMO specializing in messenger RNA (mRNA) medicines and vaccines.

The company was established as a joint venture between Axcelead, Inc., Japan’s first drug discovery platform company, and Arcturus Therapeutics, a US-based clinical-stage mRNA therapeutics company.

In July 2023, ARCALIS launched a GMP-compliant mRNA drug substance manufacturing facility in Japan, further strengthening its integrated development and manufacturing capabilities.

In 2024, the company achieved a major milestone with the world’s first commercial production of a self-amplifying mRNA vaccine against COVID-19.

mRNA technology is driving innovation beyond infectious diseases, with expanding applications in rare diseases, oncology, regenerative medicine, and genome-editing therapies.

Leveraging deep expertise in mRNA development and manufacturing, ARCALIS supports clients from early-stage research through to commercial production, ensuring a reliable supply of high-quality mRNA.

In addition, ARCALIS provides:

  • High-throughput, small-scale, multi-product services optimized for target selection and LNP (lipid nanoparticle) screening
  • Flexible engagement options, including standalone consultation for fill-finish operations at our DP (drug product) facility
    Our website TOP PAGE｜ARCALIS, Inc.

Eclipsebio is a private biotechnology company headquartered in San Diego that combines AI-powered sequence design, rapid prototyping, and sequencing-based analytics to support RNA drug development. With extensive experience supporting early-stage basic research through preclinical therapeutic development, Eclipsebio provides unparalleled support for obtaining deep insights into RNA and therapeutic biology. The company offers its solutions as end-to-end partnerships for biopharma and project-based services for academics. For more information about Eclipsebio, visit www.eclipsebio.com.

Primrose Bio develops and commercializes manufacturing technologies that close gaps in biologics, mRNA and vaccine production. Primrose’s major offerings include Pfenex Expression Technology®: a proprietary microbial production system used in six approved products with up to 20x higher yields and a strong record across diverse protein modalities; Prima RNApols®: improved enzymes for mRNA manufacturing; and PeliCRM197®: a commercially validated CRM197 carrier protein used for conjugate vaccines.  Several of the world’s leading pharmaceutical companies use Primrose’s technologies in marketed products, including Merck, Jazz Pharmaceuticals, Alvogen, and Serum Institute of India. For more information, please visit: visit: www.primrosebio.com.

Bronze Sponsors 2026

4basebio is a GMP-certified manufacturer of synthetic DNA, advancing next-generation cell and gene therapies and vaccines with fast, flexible, and high-purity synthetic nucleic acid solutions.

We design, manufacture, and supply application-specific synthetic DNA and mRNA. Our novel enzymatic DNA synthesis platform offers unique customization potential, rapid turnaround times, and enhanced safety compared to traditional plasmid DNA.

Our clinically validated opDNA® construct is optimized for mRNA production, eliminating the need for enzymatic linearization and enabling dose reductions, increased purity, and greater consistency.

To learn more, visit https://www.4basebio.com/.

Evonik Health Care is a business line of Evonik Corporation, one of the world’s leading specialty chemicals companies. The Health Care business serves as a global innovation partner to pharmaceutical, biotechnology, medical device, and nutraceutical companies, helping develop and manufacture advanced therapies that improve patient outcomes.

Founded in the mid-1970s as a collective of scientists committed to developing innovative products for the life sciences industry, New England Biolabs is proud to be a world leader in the discovery and production of enzymes for molecular biology applications.

Here’s the deal. We’re all about helping biologics and gene therapy researchers break free from tools that just don’t cut it. Unleashing problem-tackling solutions and AI-driven automation that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it.

Evonik Health Care is a business line of Evonik Corporation, one of the world’s leading specialty chemicals companies. The Health Care business serves as a global innovation partner to pharmaceutical, biotechnology, medical device, and nutraceutical companies, helping develop and manufacture advanced therapies that improve patient outcomes.

4basebio is a GMP-certified manufacturer of synthetic DNA, advancing next-generation cell and gene therapies and vaccines with fast, flexible, and high-purity synthetic nucleic acid solutions.

 

We design, manufacture, and supply application-specific synthetic DNA and mRNA. Our novel enzymatic DNA synthesis platform offers unique customization potential, rapid turnaround times, and enhanced safety compared to traditional plasmid DNA.

 

Our clinically validated opDNA® construct is optimized for mRNA production, eliminating the need for enzymatic linearization and enabling dose reductions, increased purity, and greater consistency.

 

To learn more, visit https://www.4basebio.com/.

Basic Sponsors 2026

As one of the largest independent contract laboratories in Europe, Labor LS provides analytical services to more than 1,000 clients according to cGMP standards in the fields of microbiology, biochemistry, molecular biology, and chemical-physical analysis. 
With the goal of offering comprehensive, one-stop services to support the development and release of the most advanced pharmaceutical products, Labor LS carries out method validations, verifications, and routine testing with over 600 experts and approximately 7,000 m² of laboratory space, working in close cooperation with its customers.

Immagina Bio advances RNA and ribosome biology by enabling scientists to study translation in action. Our integrated suite of technologies—including high-throughput ribosome profiling, ribosome isolation, native-tRNA sequencing, cell-free RNA fragmentomics, and RNA modification detection—delivers unprecedented insights into protein synthesis. We empower academic researchers and pharmaceutical companies to develop more efficient, effective, and safer therapeutics, along with more informative biomarkers

preclinics GmbH is a Potsdam (GER) -based leading Contract Research Organization (CRO). We are specialized in the early preclinical development of biologics, vaccines, and therapeutic candidates. Our integrated preclinical services accelerate the translation of mRNA-based therapies and vaccines from bench to clinic. 

With more than 15 years of scientific excellence, preclinics combines cutting-edge technologies, comprehensive in vitro and in vivo models, and a collaborative mindset to deliver high-quality, reliable data for decision-making in drug development. 

Our preclinical portfolio covers: 

  • Translational in vivo PK/PD models for mRNA delivery systems 
  • Reporter gene analysis via in vivo imaging, ddPCR and protein quantification 
  • Biomarker-driven efficacy studies. 
  • Immunogenicity and antibody response profiling for mRNA candidates. 
  • Formulation testing and comparative studies for LNP and non-LNP technologies.

     

We invite you to visit our representative to discuss how preclinics can advance your mRNA program — from concept to preclinical validation. 

Driven by innovation and a strong commitment to scientific integrity, animal welfare, and the 3R principles, and as a signatory of the Marseille Declaration, preclinics is your trusted partner for translational preclinical solutions that move ideas efficiently and responsibly toward clinical success. 

In collaboration with Taconic Biosciences, preclinics provides access to 4.600 transgene models and custom GEM services, empowering our partners to explore disease mechanisms and validate therapeutic targets with exceptional translational relevance. 

For more information please visit www.preclinics.com